Medical Director,
Memorial Cancer Institute (MCI),
Memorial Health Care System,
Florida
Oncology
Luis E. Raez, MD practices Oncology. He received 34 awards: "CMS Meaningful Use Stage 1 Certification", "Listed in Marquis "Who's Who in Medicine and Health Care" in America", "Listed in Marquis Who's Who in America", "Listed in Strattons Who is Who in America", "Listed in Outstanding Intellectuals of the 20th Century", "Listed in Marquis Who's Who in Science and Engineering", "Listed in Marquis Who's Who in the World", "Listed in Cambridge Whos who", "Listed in Whos Who among Executives and Professionals Throughout the World", "Honorary member", "Listed as one of The Best Doctors in America", "Promoted to: Master in the American College of Specialists in Geriatrics (MACSG)", "University of Miami/Sylvester Comprehensive Cancer Center Intramural Grant Award", "Promoted to the Fellowship in the American College of Specialists in Geriatrics", "James and Esther King Award", "Elected for the Fellowship", "Clinical Innovator Award", "Listed in the Guide to Americas Top Physicians", "Second Place", "Papanicolaou Corps Distinguished Investigator of the year", "Women's Cancer Association (WCA) Award", "Fellow (FACP)", "Promoted to the Fellowship in the American College of Physicians (ACP)", "Research Career Development Award", "Stanley J. Glaser Foundation Biomedical Research Award", "Physicians' Recognition Award in Continuing Medical Education", "Third Place", "First Place", "Outstanding Resident of the Year", "Third Place in Research Poster Presentations", "Highest GPA during 1991-1992 Internship", "Ranked in the top 10% in the 1992 graduating class", "Award of Collaboration and Dedication to Student Affairs and University Welfare" and "Super Doctor". Luis Raez is a published doctor as well. He has 67 publications published. The latest was: Successful treatment of lymphomatoid granulomatosis using cyclosporin-A after failure of intensive chemotherapy. He is registered with Medicare and accepts Medicare payments.
Publications
- Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
- Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation.
- A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histolo...
- Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck Cancer.
- A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid Tumors.
- Novel molecular targeted therapies for refractory thyroid Cancer.
- Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck Cancer.
- Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.
- Immunotherapy as a strategy for the treatment of non-small-cell lung Cancer.
- The role of proteasome inhibition in nonsmall cell lung Cancer.
- A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the Lung.
- Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung Cancer.
- Oxaliplatin in first-line therapy for advanced non-small-cell lung Cancer.
- Erlotinib (tarceva) for the treatment of non-small-cell lung Cancer and pancreatic Cancer.
- Developing a vaccine for non-small-cell lung Cancer. Commentary.
- Radiation technique influence on percutaneous endoscopic gastrostomy tube dependence: Comparison between two radiation schemes.
- Gene expression profiling and non-small-cell lung Cancer: where are we now?
- Second-line therapy for non-small-cell lung Cancer.
- Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck Cancer.
- EGFR targeting of solid Tumors.
- Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung Cancer.
- Heat shock protein-based Cancer vaccines.
- New developments in chemotherapy for advanced non-small cell lung Cancer.
- Lung Cancer immunotherapy.
- Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung Cancer.
- The utility of a bone marrow biopsy in diagnosing the source of fever of unknown origin in patients with AIDS.
- Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung Cancer.
- Chemotherapy for advanced non-small-cell lung Cancer.
- Primary hepatic non-Hodgkin's Lymphomas: case report and review of the literature.
- Cancer vaccines: a new therapeutic alternative for lung Cancer therapy?
- EGF receptor in lung Cancer: a successful story of targeted therapy.
- Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the Lung: case report and review of literature.
- Active immunotherapy for non-small-cell lung Cancer: moving toward a reality.
- Development of targeted therapy for squamous cell carcinomas of the head and neck.
- Accelerated second-line or maintenance chemotherapy versus treatment at Disease progression in NSCLC.
- Current results and future applications of radioimmunotherapy management of non-Hodgkin''s Lymphoma.
- Nasopharyngeal carcinoma: alternative treatment options after Disease progression.
- Tumor immunogenicity and responsiveness to Cancer vaccine therapy: the state of the art.
- How is gene-expression profiling going to challenge the future management of lung Cancer?
- Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung Cancer.
- Targeting important pathways in head and neck Cancer: from the bench to the clinic.
- Controversies in the management of stage IIIA non-small-cell lung Cancer.
- Sequential therapy for the locally advanced larynx and hypopharynx Cancer subgroup in TAX 324: survival, surgery, and organ preservation.
- New targets for non-small-cell lung Cancer therapy.
- Cisplatin and fluorouracil alone or with docetaxel in head and neck Cancer.
- Allogeneic tumor-cell-based vaccines secreting endoplasmic reticulum chaperone gp96.
- Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung Cancer (NSCLC).
- Present and future of lung Cancer vaccines.
- Advantage of EUS Trucut biopsy combined with fine-needle aspiration without immediate on-site cytopathologic examination.
- Induction chemotherapy in the management of squamous cell carcinoma of the head and neck.
- Successful treatment of autoImmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature.
- Pemetrexed-associated urticarial vasculitis.
- Clinical trials targeting lung Cancer with active immunotherapy: the scope of vaccines.
- DNA methylation: its role in Lung carcinogenesis and therapeutic implications.
- Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung Cancer--experience from a prematurely closed phase II study.
- Combined modality therapy for limited-disease small cell lung Cancer.
- Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive Acute lymphoblastic leukemia.
- Successful treatment of Lymphomatoid granulomatosis using cyclosporin-A after failure of intensive chemotherapy.
- Pulmonary bone marrow embolism in sickle cell Disease.
- Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central Nervous system lymphoma (PCNSL).
- Is central Nervous system prophylaxis necessary in ocular adnexal lymphoma?
- Treatment of AIDS-related primary central Nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.
- Post-liver transplantation lymphoproliferative Disorders with and without infusions of donor bone marrow cells.
- Radical resection of periampullary Tumors in the elderly: evaluation of long-term results.
- Survival of renal allograft following de novo hemolytic uremic syndrome after kidney transplantation.
- Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell Lung c...
Procedures Preformed
- Cancer Counseling
- Cancer Treatment
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Listed in Marquis "Who's Who in Medicine and Health Care" in America
- Listed in Marquis Who's Who in America
- Listed in Stratton’s Who is Who in America
- Listed in Outstanding Intellectuals of the 20th Century
- Listed in Marquis Who's Who in Science and Engineering
- Listed in Marquis Who's Who in the World
- Listed in Cambridge Who’s who
- Listed in Who’s Who among Executives and Professionals Throughout the World
- Honorary member
- Listed as one of The Best Doctors in America
- Promoted to: Master in the American College of Specialists in Geriatrics (MACSG)
- University of Miami/Sylvester Comprehensive Cancer Center Intramural Grant Award
- Promoted to the Fellowship in the American College of Specialists in Geriatrics
- James and Esther King Award
- Elected for the Fellowship
- Clinical Innovator Award
- Listed in the Guide to America’s Top Physicians
- Second Place
- Papanicolaou Corps Distinguished Investigator of the year
- Women's Cancer Association (WCA) Award
- Fellow (FACP)
- Promoted to the Fellowship in the American College of Physicians (ACP)
- Research Career Development Award
- Stanley J. Glaser Foundation Biomedical Research Award
- Physicians' Recognition Award in Continuing Medical Education
- Third Place
- First Place
- Outstanding Resident of the Year
- Third Place in Research Poster Presentations
- Highest GPA during 1991-1992 Internship
- Ranked in the top 10% in the 1992 graduating class
- Award of Collaboration and Dedication to Student Affairs and University Welfare
- Super Doctor
Education
-
Jackson Memorial Hospital - Jackson Health System
-
Cayetano Heredia University
-
University of Miami
Drug Facts
| NPI NUMBER |
|
1922030071 |
| NPPES Provider LastName |
|
RAEZ |
| NPPES Provider FirstName |
|
LUIS |
| NPPES Provider ZIPCode |
|
330281046 |
| NPPES Provider State |
|
FL |
| Specialty Description |
|
Hematology/Oncology |
| Total Claim Count |
|
498.0 |
| Distinct Opioid Count |
|
1.0 |
| Opioid Claim Count |
|
12.0 |
| Percent Opioid Claims |
|
2.41 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1922030071 |
| Last Name Of The Provider |
RAEZ |
| First Name Of The Provider |
LUIS |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.
